InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.56
(
0.14%
)
US TECH 100
17,676.80
(
0.20%
)
Dow Jones
39,500.92
(
0.29%
)
Brent Oil
82.73
(
-1.46%
)
Bitcoin
60,767.00
(
-3.62%
)
Post# of 30310
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

alexander77

Send PM Follow Ignore
Followers 51
Posts 4564
Boards Moderated 0
Alias Born 12/14/2009

alexander77

Re: None

Sunday, 02/19/2017 3:10:21 AM

Sunday, February 19, 2017 3:10:21 AM

Post# of 30310
AEZS:potential 6-/10-bagger this year:If phase3 for Zoptrex shows succesfull results in April, share price of AEZS will be ++$20/share afterwarts (before FDA decision). This because of the Adam Feuerstein biotech oncology rule: The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps< $300M. https://www.google.be/amp/s/www.thestreet.com/amp/story/12696926/1/the-feuerstein-ratain-rule-update-still-perfect-predicting-small-cap-cancer-drug-failure.html?client=safari
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up